Lipid modification and coronary heart disease in type 2 diabetes: different from the general population?

被引：10

作者：

Feher, MD ^{[1
]}

Elkeles, RS

机构：

[1] Chelsea & Westminster Hosp, Imperial Coll Sch Med, Clin Pharmacol Sect, London, England

[2] St Marys Hosp, Imperial Coll Sch Med, Metab Med Unit, London W2 1PG, England

来源：

HEART | 1999年 / 81卷 / 01期

关键词：

D O I：

10.1136/hrt.81.1.10

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10 / 11

页数：2

共 19 条

[1]

*AM HEART ASS SCI, 1997, LONG TERM INT PRAV I

[2]

CASLAKE MJ, 1997, DIABETIC MED S1, V14, pS41

[3]

Durrington P, 1997, DIABETIC MED, V14, P513, DOI 10.1002/(SICI)1096-9136(199707)14:7<513::AID-DIA427>3.0.CO

[4]

2-S

[5] Cardiovascular outcomes in type 2 diabetes - A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study [J].

Elkeles, RS ;

Diamond, JR ;

Poulter, C ;

Dhanjil, S ;

Nicolaides, AN ;

Mahmood, S ;

Richmond, W ;

Mather, H ;

Sharp, P ;

Feher, MD .

DIABETES CARE, 1998, 21 (04) :641-648

[6]

FEHER MD, 1995, BRIT HEART J, V74, P14

[7]

Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014

[8]

HOWARD BV, 1987, J LIPID RES, V28, P613

[9]

JOKEL R, 1997, DIABETES REV, V5, P316

[10] LIPIDS, DIABETES, AND CORONARY HEART-DISEASE - INSIGHTS FROM THE FRAMINGHAM-STUDY [J].

KANNEL, WB .

AMERICAN HEART JOURNAL, 1985, 110 (05) :1100-1107

← 1 2 →